ACAAI 2020 Annual Meeting - Medically Challenging Cases Abstract Submission Guidance

Medically Challenging Case Abstract
Submission Guidelines

ACAAI 2020 Annual Scientific Meeting

The Changing Practice Landscape - RISING to the CHALLENGE
Phoenix, AZ
November 12-16

Submission Deadline: August 2, 2020

Medically Challenging Cases (MCC)

The College invites you to submit an abstract for the 2020 Annual Scientific Meeting, November 12-16 in Phoenix. The theme of the meeting is: The Changing Practice Landscape - RISING to the CHALLENGE.

New for 2020!

Medically Challenging Case Submission 
The deadline for case submission is 11:59 PM (CDT) on August 2, 2020. Cases must be submitted electronically via the online form, and they must be complete, including the author listing. ACAAI will not accept any cases or changes to cases after the submission deadline. Case changes include: changes to title or body, changes to presenting authors, author additions, revised author names, and/or revised author listing. This deadline applies to ALL Medically Challenging Case abstract submissions.

Submission Fee
There is a $60 non-refundable fee for each abstract submission. Payment does not guarantee that the abstract will be accepted. Payment must be made by credit card (Visa, MasterCard or American Express). Purchase orders and checks will not be accepted.

Medically Challenging Case (MCC) Presentations

1. MCCs are an opportunity to present interesting and challenging cases you have managed in your hospital or practice.
2. ACAAI only accepts original cases. Cases previously accepted and/or published by other organizations should not be submitted. If a case submitted to ACAAI is accepted for programming and/or publication by another organization prior to its acceptance by ACAAI, it must be withdrawn from consideration for the ACAAI Annual Meeting. An individual can only be the presenting author on one abstract. If submitting more than one abstract, you will have to identify co-authors as the presenter(s) for other abstracts. If you are the submitting author and the presenting author, you must list your name in the author listing and select the role of "Presenting Author." We will not make the assumption that the submitting author is the presenting author.
3. As the submitter, you will be the main contact person for the abstract, and as such, it will be your responsibility to make sure the other authors are informed of any communications from ACAAI regarding the abstract (including requests from the Abstract Review Subcommittee for additional information, disposition and placement decision, missing disclosures, etc.). If you are unwilling or unable to function in this capacity, please designate someone else as the contact person.
4. It is the responsibility of the submitting author to ensure accuracy of content, spelling and author information, including listing order. Abstracts are directly exported from the submission database for publication.
5. Please review your submission carefully to make sure that all appropriate data and all authors are listed and in the correct order. Absolutely no changes to body copy, data or authors will be accepted after the submission deadline of August 2, 2020, 11:59 pm (CDT).

Abstract Withdrawal
If the Presenting Author wishes to withdraw his/her case from the Annual Meeting program, a written request must be submitted to education@acaai.org by August 2, 2020. Any request for withdrawal after that date cannot be assured removal from the ACAAI's official journal, the Annals of Allergy & Immunology or other ACAAI Annual Meeting publications or references.

Abstract Author Disclosure of Financial Relationships
Abstracts may be submitted by fellows, members and non-members of the College. Employees of pharmaceutical or medical device companies or other ACCME-defined commercial interests are prohibited from participating as an author or presenter of an oral abstract; however, they may participate as an author or presenter for the poster session.

An ACCME-defined commercial interest is, “any entity producing, marketing, reselling or distributing healthcare goods or services used on, or consumed by, patients.”

All authors must complete the online Disclosure of Financial Relationships by August 2, 2020 or their names will be pulled as an abstract author.

Disclosure of relevant financial relationships includes the commercial interest name, the role played, and what was received.

1. Type of relationships include: employee, consultant/advisor, speaker, supported/contracted research, patent holder/royalty IPR, board member (for profit organizations), author/editor
2. Types of financial incentives received include: salary, ownership interests (stocks or other ownership interests, excluding diversified mutual funds), consulting fees, honorarium, grants, royalty, intellectual property rights, or other financial benefit

The ACCME has not set a minimum dollar amount for relationships to be considered relevant and does not use the term significant to describe financial relationships. Inherent in any amount is the incentive to maintain or increase the value of the relationship.

Commercial Bias
All abstracts must be devoid of commercial bias. Trade names should not be used in referencing drugs, devices or instrumentation. Any medications or other substances referred to in the presentation material should be identified by their generic name or description. Trade name violations/commercial bias will result in below average scores or rejection. Failure to disclose financial relationships with ACCME-defined commercial interests will prohibit an author/presenter from participating in oral and poster sessions.

HERE'S WHAT YOU WILL NEED TO SUBMIT FOR EACH AUTHOR:

1. You must list your authors in the order in which they should appear in the abstract. If you are the presenting author, your name needs to be listed first. A limit of 10 authors per abstract may be included.
2. First Name, Middle Initial and Last Name
3. Company/Institution Name
4. City, State and Country (where employed)
5. Author Email
6. All authors listed on your abstract will receive an email with a link for completing their disclosure. Please make sure they respond; all authors listed on your abstract are REQUIRED to disclose and it will be your responsibility as the Submitter and/or Presenting Author to follow-up with the other authors to make sure the disclosures have been submitted. They will continue to receive auto-reminders each time an abstract is revised or submitted until they have complied with the disclosure request.
7. Your abstract WILL NOT be reviewed unless all listed authors have: a) approved the submission of the abstract for consideration for presentation at the ACAAI 2020 Annual Meeting; and b) completed and submitted their online disclosure by August 2, 2020.

ORGANIZATION OF ABSTRACT BODY

Abstract Length
There is a limit of 15 words for the title and 250 words for the body of your abstract submission.

Each abstract should contain:

1. Title: (A brief introduction indicating the reason for the study
2. Introduction
3. Case Description
4. Discussion

Submitting a COVID-19 abstract? Please read the following:

1. The intent of this category is to present to colleagues the challenging aspect of an individual case presentation (difficult diagnosis, unexpected responses to intervention and/or outcomes) and how the clinician authors addressed the challenge. This category is not intended to be overly speculative in terms of possible associations or presenting new standard-of-care, but rather to provide the reader with an inner-view of the author(s)' throught process.

Be sure to use "Introduction", "Case Description" and "Discussion" in the body of your abstract to indicate the start of each new section. The abstract title and author information should not be included in the body of the abstract.

Best results are achieved copying and pasting directly from a Word document. Please make sure that you use the "Insert Symbols" feature in Word for any mathematical, Latin or scientific expressions. If you are entering the copy directly onto the Abstract Form, you must use the “Symbols” icon to ensure your result is displayed accurately. Always verify that your information is correct prior to submitting by selecting "Print Preview."

Title Guidelines
Capitalize only the first letter of each word of the title. Do not use formatting tags in the title. The title will be formatted automatically by the system at the time of print production. Abbreviations must not be used in the title.

Editorial Policies for Authors (ICMJE Guidance)
Reproduced Materials - When previously published figures or tables are used, the author must obtain written permission from the copyright holder (usually the publisher) to reproduce the material in print and online. An appropriate credit line should be included in the figure legend or table footnote, and full publication information should be cited in the reference list. Letters of permission must accompany the manuscript at the time of submission.

Commercial Bias
All abstracts must be devoid of commercial bias. Trade names should not be used in referencing drugs, devices or instrumentation. Any medications or other substances referred to in the presentation material should be identified by their generic name or description. Trade name violations/commercial bias will result in below average scores or rejection.

Use of Figures
You may add one figure to your abstract, however, it is recommended that results be shown in narrative form, since figure formats may be compromised in publication. The figure must be submitted as a jpg file and cannot exceed 500kb.

Medically Challenging Case Acceptance
If the abstract is accepted for presentation at the 2020 ACAAI Annual Meeting, the submitting author will be notified via email in early September. Only the submitting author will be notified of abstract programming. Please make sure all contact information is accurate. The notification will include the scheduled date, time and location of the presentation.

For your convenience, all accepted posters for the 2020 ACAAI Annual Meeting will be displayed electronically. Complete details regarding the electronic posters will be sent to the submitting author of accepted abstracts in early September. Abstracts scheduled for presentation will be grouped by topic, numbered and listed in the program and published in the ACAAI'S official journal, the Annals of Allergy, Asthma and Immunology abstract supplement. The decision of the ACAAI Abstract Review Subcommittee regarding acceptance and presentation of abstracts is final.

Meeting Registration
All authors who will be attending the Annual Meeting must register online for the meeting and pay any applicable registration fees. The meeting registration site will open in August.